QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M 3 Selective Receptor Antagonist for the Treatment of Overactive Bladder
Prolongation of QT interval on an electrocardiogram is a valuable predictor of a drug's ability to cause potentially fatal ventricular tachyarrhythmia (torsades de pointes). Darifenacin is a muscarinic M 3 selective receptor antagonist developed for the treatment of overactive bladder, a debili...
Saved in:
| Published in: | Journal of clinical pharmacology Vol. 45; no. 9; pp. 1038 - 1047 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
01-09-2005
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Prolongation of QT interval on an electrocardiogram is a valuable predictor of a drug's ability to cause potentially fatal ventricular tachyarrhythmia (torsades de pointes). Darifenacin is a muscarinic M
3
selective receptor antagonist developed for the treatment of overactive bladder, a debilitating condition that is particularly prevalent in the older population. This 7‐day, randomized, parallel‐group study (n = 188) measured QT/QTc interval in healthy volunteers receiving once‐daily darifenacin at steady‐state therapeutic (15 mg) and supratherapeutic (75 mg) doses, alongside controls receiving placebo or moxifloxacin (positive control, 400 mg) once daily. There was no significant increase in QTcF interval with darifenacin treatment compared with placebo. Mean changes from baseline at pharmacokinetic T
max
versus placebo were −0.4 and −2.2 milliseconds in the darifenacin 15 mg and 75 mg groups, respectively, compared with +11.6 milliseconds in the moxifloxacin group (P <.01). This study demonstrates that darifenacin does not prolong QT/QTc interval. |
|---|---|
| AbstractList | Prolongation of QT interval on an electrocardiogram is a valuable predictor of a drug's ability to cause potentially fatal ventricular tachyarrhythmia (torsades de pointes). Darifenacin is a muscarinic M
3
selective receptor antagonist developed for the treatment of overactive bladder, a debilitating condition that is particularly prevalent in the older population. This 7‐day, randomized, parallel‐group study (n = 188) measured QT/QTc interval in healthy volunteers receiving once‐daily darifenacin at steady‐state therapeutic (15 mg) and supratherapeutic (75 mg) doses, alongside controls receiving placebo or moxifloxacin (positive control, 400 mg) once daily. There was no significant increase in QTcF interval with darifenacin treatment compared with placebo. Mean changes from baseline at pharmacokinetic T
max
versus placebo were −0.4 and −2.2 milliseconds in the darifenacin 15 mg and 75 mg groups, respectively, compared with +11.6 milliseconds in the moxifloxacin group (P <.01). This study demonstrates that darifenacin does not prolong QT/QTc interval. |
| Author | Wang, Yibin Bedigian, Martin P. Milosavljev, Slavica Affrime, Melton B. Greig, Gerard Skerjanec, Andrej Serra, Denise B. |
| Author_xml | – sequence: 1 givenname: Denise B. surname: Serra fullname: Serra, Denise B. – sequence: 2 givenname: Melton B. surname: Affrime fullname: Affrime, Melton B. – sequence: 3 givenname: Martin P. surname: Bedigian fullname: Bedigian, Martin P. – sequence: 4 givenname: Gerard surname: Greig fullname: Greig, Gerard – sequence: 5 givenname: Slavica surname: Milosavljev fullname: Milosavljev, Slavica – sequence: 6 givenname: Andrej surname: Skerjanec fullname: Skerjanec, Andrej – sequence: 7 givenname: Yibin surname: Wang fullname: Wang, Yibin |
| BookMark | eNpdkM1OwzAQhC1UJNrCneM-AAE7zu-xtPxUalWVBnGMHHtNg1Inst1KPA8vSgKcOK12vt0ZaSZkZFqDhFwzestYmt5RmrMwpZTGYZpTRs_ImMVxGEQJjUZkPOBg4Bdk4twHpSyJYjYmX9sChFGwLSQsjUd7Eg281X4PO9_rwqofvDt2Vvg9WtHh0dcSFq1DB62GhbC1RiNkbW5AwProZK-Y_mQNHHbYoPT1CeEFJXa-tTAzXry3pnYedL_2plBYFP6Axg-Gm1Of8vtz3wil0F6Scy0ah1d_c0peHx-K-XOw2jwt57NVIFme-YDlqVJSxzznKJlKMqW1qHiIaZLGkcpzIVWmY5pxJnUV8iSJKqwUj7OMh5mO-JTQX19pW-cs6rKz9UHYz5LRcii5_F8y_wb3BHLj |
| CitedBy_id | crossref_primary_10_1038_sj_bjp_0706678 crossref_primary_10_1111_j_1464_410X_2006_06439_x crossref_primary_10_1185_03007995_2011_585395 crossref_primary_10_1007_BF03256697 crossref_primary_10_1586_17512433_1_6_815 crossref_primary_10_2165_00003088_200645040_00001 crossref_primary_10_1007_s40261_013_0058_0 crossref_primary_10_1517_14656566_2011_554399 crossref_primary_10_1177_0091270008330158 crossref_primary_10_1017_S0959259809990475 crossref_primary_10_1080_14740338_2018_1453496 crossref_primary_10_1517_17425255_2012_714365 crossref_primary_10_1016_j_ahj_2011_11_009 crossref_primary_10_1016_j_clinthera_2008_02_002 crossref_primary_10_1111_j_1476_5381_2009_00427_x crossref_primary_10_1038_clpt_2012_181 crossref_primary_10_1007_s11884_008_0007_6 crossref_primary_10_1111_j_1365_2125_2008_03250_x crossref_primary_10_1007_s11934_007_0032_6 crossref_primary_10_1016_j_eururo_2007_02_057 crossref_primary_10_1016_j_ucl_2006_06_007 crossref_primary_10_1038_nrurol_2011_7 crossref_primary_10_1177_0091270008319330 crossref_primary_10_1517_14740338_2013_813016 crossref_primary_10_1016_j_ejphar_2020_173707 crossref_primary_10_2217_17455057_1_3_331 crossref_primary_10_1038_sj_bjp_0706780 crossref_primary_10_1111_j_1476_5381_2009_00487_x crossref_primary_10_1177_0091270008318007 crossref_primary_10_1177_0091270009337511 crossref_primary_10_1155_2011_820816 crossref_primary_10_1038_sj_clpt_6100328 crossref_primary_10_1080_10543400801993002 crossref_primary_10_2147_ciia_2006_1_4_309 crossref_primary_10_1016_j_juro_2008_01_001 crossref_primary_10_1007_s40264_013_0016_z crossref_primary_10_1038_sj_clpt_6100089 crossref_primary_10_1517_14656566_8_4_511 crossref_primary_10_2165_11592790_000000000_00000 crossref_primary_10_2217_1745509X_3_2_143 crossref_primary_10_1007_s41999_023_00798_7 crossref_primary_10_1177_0091270010379809 crossref_primary_10_1185_03007990802278453 crossref_primary_10_1185_030079907X233160 crossref_primary_10_1177_1479164112445755 |
| Cites_doi | 10.1016/j.amjcard.2004.02.034 10.1067/mcp.2002.125783 10.1038/nrd1108 10.1046/j.1365-2680.2001.00231.x 10.1046/j.1542-474X.2003.08413.x 10.1016/S0022-5347(18)37789-9 10.1136/bmj.302.6790.1469-c 10.1111/j.1464-410X.2005.05454.x 10.1136/hrt.74.1.53 10.1046/j.1464-410x.2001.02228.x 10.1056/NEJMra032426 10.1016/S1569-9056(02)00045-3 10.1016/S0022-5347(18)37797-8 10.1016/0140-6736(91)90481-4 10.1021/ac9507552 10.1001/jama.289.16.2120 10.1080/004982598238859 10.1016/S0024-3205(98)00585-2 10.1124/jpet.104.067140 10.1067/mcp.2000.111482 10.1093/ajhp/58.5.379 10.1016/0002-9149(93)90035-B |
| ContentType | Journal Article |
| DBID | AAYXX CITATION |
| DOI | 10.1177/0091270005279010 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1552-4604 |
| EndPage | 1047 |
| ExternalDocumentID | 10_1177_0091270005279010 |
| GroupedDBID | --- .55 .GJ 05W 0R~ 123 18M 1CY 1OB 1OC 29K 33P 34G 39C 3O- 3SF 4.4 52U 52V 53G 5RE 8-1 A00 AAESR AAEVG AAHHS AAMNL AANLZ AAONW AASGY AAWTL AAXRX AAYOK AAYXX AAZKR ABCUV ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXME ACXQS ADBBV ADBTR ADEOM ADIZJ ADMGS ADOZA ADXAS AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AHBTC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AUVAJ AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BOGZA BRXPI C45 CAG CITATION COF CS3 D-I DCZOG DPXWK DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F5P FEDTE FUBAC G-S GODZA GWYGA H13 HF~ HGLYW HVGLF IAO IEA IHR INH INR IVC KBYEO LATKE LEEKS LH4 LOXES LSO LUTES LW6 LYRES M4V MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A O66 O9- OVD P2P P2W PALCI PQQKQ R.K RIWAO RJQFR ROL SAMSI SUPJJ SV3 TEORI VH1 WBKPD WH7 WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR WYJ X7M YCJ ZGI ZXP ZZTAW |
| ID | FETCH-LOGICAL-c198t-197ddcf5393ec1d68dffab32e76754d99acd8f50831cfb23664bebd3588328f43 |
| ISSN | 0091-2700 |
| IngestDate | Thu Nov 21 21:20:18 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c198t-197ddcf5393ec1d68dffab32e76754d99acd8f50831cfb23664bebd3588328f43 |
| PageCount | 10 |
| ParticipantIDs | crossref_primary_10_1177_0091270005279010 |
| PublicationCentury | 2000 |
| PublicationDate | 2005-09-01 |
| PublicationDateYYYYMMDD | 2005-09-01 |
| PublicationDate_xml | – month: 09 year: 2005 text: 2005-09-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationTitle | Journal of clinical pharmacology |
| PublicationYear | 2005 |
| References | e_1_2_5_26_2 e_1_2_5_27_2 e_1_2_5_25_2 Napier CP (e_1_2_5_6_2) 2002 e_1_2_5_23_2 e_1_2_5_20_2 e_1_2_5_21_2 e_1_2_5_28_2 e_1_2_5_29_2 e_1_2_5_13_2 e_1_2_5_16_2 e_1_2_5_15_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_5_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_4_2 e_1_2_5_11_2 Bazett HC (e_1_2_5_14_2) 1920; 7 European Medicines Evaluation Agency. (e_1_2_5_24_2) 2002 e_1_2_5_3_2 World Medical Association. (e_1_2_5_22_2) 2002; 48 e_1_2_5_2_2 Stevens L (e_1_2_5_9_2) 2004; 171 e_1_2_5_18_2 e_1_2_5_17_2 Stevens L (e_1_2_5_8_2) 2004; 171 e_1_2_5_19_2 e_1_2_5_30_2 |
| References_xml | – ident: e_1_2_5_19_2 doi: 10.1016/j.amjcard.2004.02.034 – ident: e_1_2_5_26_2 doi: 10.1067/mcp.2002.125783 – ident: e_1_2_5_13_2 doi: 10.1038/nrd1108 – ident: e_1_2_5_7_2 doi: 10.1046/j.1365-2680.2001.00231.x – ident: e_1_2_5_15_2 doi: 10.1046/j.1542-474X.2003.08413.x – volume-title: ICH E14 document: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐arrhythmic drugs year: 2002 ident: e_1_2_5_24_2 contributor: fullname: European Medicines Evaluation Agency. – volume: 171 start-page: 140 year: 2004 ident: e_1_2_5_9_2 article-title: Muscarinic receptor function in the idiopathic overactive bladder [abstract] publication-title: J Urol doi: 10.1016/S0022-5347(18)37789-9 contributor: fullname: Stevens L – ident: e_1_2_5_28_2 doi: 10.1136/bmj.302.6790.1469-c – ident: e_1_2_5_31_2 doi: 10.1111/j.1464-410X.2005.05454.x – ident: e_1_2_5_21_2 – ident: e_1_2_5_29_2 doi: 10.1136/hrt.74.1.53 – ident: e_1_2_5_2_2 doi: 10.1046/j.1464-410x.2001.02228.x – ident: e_1_2_5_11_2 doi: 10.1056/NEJMra032426 – ident: e_1_2_5_10_2 doi: 10.1016/S1569-9056(02)00045-3 – volume: 171 start-page: 143 year: 2004 ident: e_1_2_5_8_2 article-title: A comparison of muscarinic receptor‐mediated function in the normal and the neurogenic overactive bladder [abstract] publication-title: J Urol doi: 10.1016/S0022-5347(18)37797-8 contributor: fullname: Stevens L – ident: e_1_2_5_27_2 doi: 10.1016/0140-6736(91)90481-4 – ident: e_1_2_5_23_2 doi: 10.1021/ac9507552 – ident: e_1_2_5_20_2 – ident: e_1_2_5_12_2 doi: 10.1001/jama.289.16.2120 – ident: e_1_2_5_25_2 doi: 10.1080/004982598238859 – ident: e_1_2_5_4_2 doi: 10.1016/S0024-3205(98)00585-2 – ident: e_1_2_5_5_2 doi: 10.1124/jpet.104.067140 – start-page: 21 year: 2002 ident: e_1_2_5_6_2 article-title: Darifenacin is selective for the human recombinant M3 receptor subtype [abstract] publication-title: Neurourol Urodyn contributor: fullname: Napier CP – ident: e_1_2_5_3_2 doi: 10.1046/j.1464-410x.2001.02228.x – ident: e_1_2_5_17_2 doi: 10.1067/mcp.2000.111482 – ident: e_1_2_5_18_2 doi: 10.1093/ajhp/58.5.379 – volume: 48 start-page: 206 year: 2002 ident: e_1_2_5_22_2 article-title: Declaration of Helsinki: ethical principles for medical research involving human subjects publication-title: J Postgrad Med contributor: fullname: World Medical Association. – volume: 7 start-page: 353 year: 1920 ident: e_1_2_5_14_2 article-title: An analysis of the time relationship to the electrocardiogram publication-title: Heart contributor: fullname: Bazett HC – ident: e_1_2_5_16_2 doi: 10.1016/0002-9149(93)90035-B – ident: e_1_2_5_30_2 |
| SSID | ssj0016451 |
| Score | 2.0228634 |
| Snippet | Prolongation of QT interval on an electrocardiogram is a valuable predictor of a drug's ability to cause potentially fatal ventricular tachyarrhythmia... |
| SourceID | crossref |
| SourceType | Aggregation Database |
| StartPage | 1038 |
| Title | QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M 3 Selective Receptor Antagonist for the Treatment of Overactive Bladder |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9tAEF6c9NJL6ZO-mUMJFFutpd3V49g0bnNxaxMVegurfYRCsI0cB_J7-kc7o5VWwjTQHHoRQmvPIs3H7OzM7DeMveOcp5WMTZTkVUUbFBcpl_NoanVsnLSiSOm88-lZ9u1nfjITs9Go6x3aP_uvmsZnqGs6OXsHbQeh-ADvUed4Ra3j9Z_0viybfMCy1D7ad00RcQq2nnVBg6ZYc7ep1eDsFTrSW08_e4KbZ2dXSntyATWe77ZaUZ5Hj-djjsbl0ttI8jjtBrfsRECgLtZEwRuKFstQv44iv-NHVP4_x5dk6epbXOJwTHPTE2qHkD9atdonpyxOhaI-BLA6R00KmtiupS7Zg7FjXJwvfvkor6dMGC_C4FdqS-ozA3XLLhAiIDKUeAWrXsR0rs7nd2xryGUSidS3Nu4svSeubBFdDMw2scQPXACir_j78tIkuGk-mm4qk4yqW_qltCsf2FthQ91j3JGr70k4YPfwhpOd5nwRsmCpkL7jY_t-fZr9476EgVs18I_Kh-xBq0X45BH5iI3s6jE7WnhF3kyg7MG2ncARLAYqfsJ-L0tAXALCFjrYAsEWOtg2w_uwhQa2sHYwgO0EFPSghTlwCKCFDrTQgxYQtIBCIYCWBPaghRa0T9mPL7Py82nU9g-JdFzkV1FcZMZoJ3nByfKkuXFOVTyxRGAkTFEobXJH_RBi7aqEp6mobGW4zHGZy53gz9jhar2yzxmktkKrJhEXMhOaoxOPS6Oa2nSqMmGsfsHed5__fONpYs5vU_bLO_z2FbvfI_41O7yqd_YNO9ia3dsGKn8Aoumwsw |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Wiley-Blackwell |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=QT+and+QTc+Interval+With+Standard+and+Supratherapeutic+Doses+of+Darifenacin%2C+a+Muscarinic+M+3+Selective+Receptor+Antagonist+for+the+Treatment+of+Overactive+Bladder&rft.jtitle=Journal+of+clinical+pharmacology&rft.au=Serra%2C+Denise+B.&rft.au=Affrime%2C+Melton+B.&rft.au=Bedigian%2C+Martin+P.&rft.au=Greig%2C+Gerard&rft.date=2005-09-01&rft.issn=0091-2700&rft.eissn=1552-4604&rft.volume=45&rft.issue=9&rft.spage=1038&rft.epage=1047&rft_id=info:doi/10.1177%2F0091270005279010&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_0091270005279010 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-2700&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-2700&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-2700&client=summon |